Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice

The present study aimed at characterizing the subcutaneous development of the Walker 256 (W256) AR tumor, a regressive variant of the rat W256 A tumor. Wistar rats were injected subcutaneously with 4x10(6) W256 A or W256 AR tumor cells. The development of tumors was evaluated daily by percutaneous measurements. None of the W256 A tumors (n=20) regressed, but 62% of the W256 AR tumor-bearing rats (n=21) underwent complete tumor regression within 35 days. Continuous growth of AR tumors was characterized by an increase of the tumor growth rate from day 12, which reached values above 1.0 g/day, and were significantly higher (p<0.05) than those of the regressive AR tumors. Immunosuppression by irradiation before subcutaneous injection of AR cells completely abrogated tumor regression and was associated with severe metastatic dissemination. Daily evaluation of the tumor growth rate enabled the discrimination, in advance, between continuously growing tumors and those that regressed later on.

Download Full-text

14 Deceleration of tumor growth after irradiation of tumor-bearing mice and transplanted tumor cells with polichromatic visible and infrared light

Photodiagnosis and Photodynamic Therapy ◽

10.1016/s1572-1000(12)70015-7 ◽

2012 ◽

Vol 9 ◽

pp. S5 ◽

Cited By ~ 1

Author(s):

V.V. Kosheverova ◽

N.A. Knyazev ◽

N.A. Filatova ◽

K.A. Samoilova

Keyword(s):

Tumor Growth ◽

Tumor Cells ◽

Infrared Light ◽

Transplanted Tumor ◽

Tumor Bearing

Download Full-text

Effects of Oral Administration of Fucoidan Extracted from Cladosiphon okamuranus on Tumor Growth and Survival Time in a Tumor-Bearing Mouse Model

Marine Drugs ◽

10.3390/md10102337 ◽

2012 ◽

Vol 10 (12) ◽

pp. 2337-2348 ◽

Cited By ~ 40

Author(s):

Kazuo Azuma ◽

Toshitsugu Ishihara ◽

Hiroyuki Nakamoto ◽

Takao Amaha ◽

Tomohiro Osaki ◽

...

Keyword(s):

Mouse Model ◽

Oral Administration ◽

Tumor Growth ◽

Survival Time ◽

Tumor Bearing Mouse ◽

Growth And Survival ◽

Tumor Bearing ◽

Cladosiphon Okamuranus

Download Full-text

Ganoderma formosanum Exopolysaccharides Inhibit Tumor Growth via Immunomodulation

International Journal of Molecular Sciences ◽

10.3390/ijms222011251 ◽

2021 ◽

Vol 22 (20) ◽

pp. 11251

Author(s):

Hsing-Chun Kuo ◽

Yen-Wenn Liu ◽

Chi-Chin Lum ◽

Kai-Di Hsu ◽

Shin-Ping Lin ◽

...

Keyword(s):

Tumor Growth ◽

Carcinoma Cell ◽

Culture Conditions ◽

Lymphocyte Subpopulation ◽

Mice Model ◽

Cytokine Mrna ◽

Antitumor Effects ◽

Tumor Bearing ◽

Therapeutic Model ◽

Ganoderma Formosanum

Ganoderma formosanum (GF) is a medicinal mushroom endemic to Taiwan. Previous research established the optimal culture conditions to produce exopolysaccharide rich in β-glucan (GF-EPS) from submerged fermentation of GF. The present study investigated the antitumor effects of GF-EPS in a Lewis lung carcinoma cell (LLC1) tumor-bearing mice model. In the preventive model, GF-EPS was orally administered to mice before LLC1 injection. In the therapeutic model, GF-EPS oral administration was initiated five days after tumor cell injection. The tumor size and body weight of the mice were recorded. After sacrifice, the lymphocyte subpopulation was analyzed using flow cytometry. Spleen tissues were used to analyze cytokine mRNA expression. The results showed that GF-EPS (80 mg/kg) effectively suppressed LLC1 tumor growth in both the preventive and therapeutic models. GF-EPS administration increased the proportion of natural killer cells in the spleen and activated gene expression of several cytokines. Our results provide evidence that GF-EPS promotes tumor inhibition through immunomodulation in tumor-bearing mice.

Download Full-text

The effects of recombinant human GH on promoting tumor growth depend on the expression of GH receptor in vivo

Journal of Endocrinology ◽

10.1530/joe-11-0100 ◽

2011 ◽

Vol 211 (3) ◽

pp. 249-256 ◽

Cited By ~ 7

Author(s):

Yan Lin ◽

Suyi Li ◽

Peng Cao ◽

Lu Cheng ◽

Ming Quan ◽

...

Keyword(s):

Gastric Cancer ◽

Tumor Growth ◽

Safety Concern ◽

Severe Malnutrition ◽

High Dose ◽

Gastric Adenoma ◽

Malignant Diseases ◽

Gh Receptor ◽

Tumor Bearing

Cancer-related malnutrition is a mortal threat to gastric carcinoma patients. However, conventional nutrition treatment is not effective for recovery. Recombinant human GH (rhGH) is widely accepted clinically to treat severe malnutrition caused by non-malignant diseases, but not approved to treat malignant diseases due to the safety concern. To explore the safety of rhGH on gastric cancer, we assessed the effect of rhGH on two tumor-bearing mice modelsin vivoestablished by human gastric adenoma cell lines of SGC-7901 and MKN-45. VEGF expression in tumor tissues was detected using immunohistochemistry. The expression of GH receptor (Ghr),Jak-2,Stat3,Vegf, Hif-1α, Fgf, andMmp-2was measured by RT-PCR and protein expression of STAT3, phosphorylated STAT3, VEGF, HIF-1α, and MMP-2 was measured by western blotting. The immunocytochemistry results showed that the GHR expression of SGC-7901 was strongly positive (GHR+++), while GHR expression of MKN-45 was regarded as negative (GHR−). After 14 days of rhGH treatment in SGC-7901 (GHR+++) tumor-bearing mice, we found that the tumor growth was significantly increased, and the expressions of downstream factors and VEGF were increased. However, in MKN-45 (GHR−) tumor-bearing mice, tumor growth was not significantly increased by rhGH, but tumor-free body weight was increased especially in high-dose rhGH-treated group (P<0.05). These findings suggest that the level of GHR expression is a key target that influences the effectiveness of rhGH on promoting the growth of gastric cancer and angiogenesis. rhGH may promote the activation of tumor angiogenesis factors through the Jak-2–STAT3 pathway.

Download Full-text

LINC01133 hampers the development of gastric cancer through increasing SST via binding to microRNA-576-5p

Epigenomics ◽

10.2217/epi-2020-0377 ◽

2021 ◽

Author(s):

Leiyi Zhang ◽

Ke Pan ◽

Zhongkun Zuo ◽

Fei Ye ◽

Ding Cao ◽

...

Keyword(s):

Gastric Cancer ◽

Tumor Growth ◽

Nude Mice ◽

Therapeutic Targets ◽

Loss Of Function ◽

Gain Of Function ◽

Tumor Bearing ◽

New Therapeutic Targets ◽

Low Expression ◽

Development Of Gastric Cancer

Aim: Our study aimed at investigating how LINC01133 functions in gastric cancer (GC) progression. Materials & methods: Gain-of-function and loss-of-function approaches were applied to analyze the effects of LINC01133, microRNA-576-5p (miR-576-5p) and somatostatin (SST) on the biological behaviors of GC cells and in tumor-bearing nude mice. Results: GC tissues and cells showed low expression of LINC01133, and LINC01133 overexpression decreased malignant phenotypes of GC cells. Moreover, LINC01133 upregulated SST through binding to miR-576-5p. Overexpressing miR-576-5p or suppressing SST reversed the functions of LINC01133 in biological potentials of GC cells and tumor growth. Conclusion: LINC01133 overexpression may inhibit GC development by downregulation of miR-576-5p and upregulation of SST, which suggests new therapeutic targets for GC.

Download Full-text

Metabolomic profiling of tumor-infiltrating macrophages during tumor growth

Cancer Immunology Immunotherapy ◽

10.1007/s00262-020-02622-8 ◽

2020 ◽

Vol 69 (11) ◽

pp. 2357-2369

Author(s):

Naoki Umemura ◽

Masahiro Sugimoto ◽

Yusuke Kitoh ◽

Masanao Saio ◽

Hiroshi Sakagami

Keyword(s):

T Cells ◽

Tumor Growth ◽

Cd8 T Cells ◽

Early Stage ◽

Suppressor Cells ◽

Tca Cycle ◽

Tumor Stage ◽

Cell Number ◽

Tumor Bearing ◽

Intracellular Metabolism

Abstract Myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) are both key immunosuppressive cells that contribute to tumor growth. Metabolism and immunity of tumors depend on the tumor microenvironment (TME). However, the intracellular metabolism of MDSCs and TAMs during tumor growth remains unclear. Here, we characterized CD11b+ cells isolated from a tumor-bearing mouse model to compare intratumoral TAMs and intrasplenic MDSCs. Intratumoral CD11b+ cells and intrasplenic CD11b+ cells were isolated from tumor-bearing mice at early and late stages (14 and 28 days post-cell transplantation, respectively). The cell number of intrasplenic CD11b+ significantly increased with tumor growth. These cells included neutrophils holding segmented leukocytes or monocytes with an oval nucleus and Gr-1hi IL-4Rαhi cells without immunosuppressive function against CD8 T cells. Thus, these cells were classified as MDSC-like cells (MDSC-LCs). Intratumoral CD11b+ cells included macrophages with a round nucleus and were F4/80hi Gr-1lo IL-4Rαhi cells. Early stage intratumoral CD11b+ cells inhibited CD8 T cells via TNFα. Thus, this cell population was classified as TAMs. Metabolomic analyses of intratumoral TAMs and MDSC-LCs during tumor growth were conducted. Metabolic profiles of intratumoral TAMs showed larger changes in various metabolic pathways, e.g., glycolysis, TCA cycle, and glutamic acid pathways, during tumor growth compared with MDSL-LCs. Our findings demonstrated that intratumoral TAMs showed an immunosuppressive capacity from the early tumor stage and underwent intracellular metabolism changes during tumor growth. These results clarify the intracellular metabolism of TAMs during tumor growth and contribute to our understanding of tumor immunity.

Download Full-text